BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer

• Type of Material: Article
• Authors: Rajesh Valanparambil, Emory University; Lilin Lai, Emory University; Margaret Johns, Emory University; Meredith Davis-Gardner, Emory University; Susanne Linderman, Emory University; Tarrant Oliver McPherson, Emory University; Andres Chang, Emory University; Akil Akhtar, Emory University; Estefany L. Bocangel Gamarra, Emory University; Hayley V. Matia, Emory University; Ashley A. McCook-Veal, Emory University; Jeffrey M. Switchenko, Emory University; Tahseen H. Nasti, Emory University; Felicia Green, Emory University; Manpreet Saini, Emory University; Andreas Wieland, Emory University; Benjamin A. Pinsky, Stanford University; Daniel Solis, Stanford University; Madhav V. Dhodapkar, Emory University; Jennifer Carlisle, Emory University; Suresh S Ramalingam, Emory University; Rafi Ahmed, Emory University; Mehul Suthar, Emory University
• Language: English
• Date: 2023-11-21
• Publisher: npj
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2023
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): https://doi.org/10.1038/s41541-023-00779-8
• Title of Journal or Parent Work: Vaccines
• Volume: 8
• Start Page: 179
• Grant/Funding Information: This work was supported in part by grants (NIH P51 OD011132, 3U19AI057266-17S1, 1U54CA260563, NIH/NIAID CEIRR CEIRS contracts HHSN272201400004C and 75N93021C00017) from the National Institute of Allergy and Infectious Diseases (NIAID), by The Oliver S. and Jennie R. Donaldson Charitable Trust, Emory Executive Vice President for Health Affairs Synergy Fund award, the Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children’s Healthcare of Atlanta, COVID-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine, Woodruff Health Sciences Center 2020 COVID-19 CURE Award. Research reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under Award Number P50CA217691. Research reported in this publication was supported in part by the Biostatistics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We acknowledge the support of Cancer Tissue and Pathology, Data and Technology Applications, and Biostatistics shared resource of the Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. M.V.D. is supported in part by R35CA197603.
• Keywords: RNA vaccines; Non-small-cell lung cancer
• Research Categories: Health Sciences, Immunology; Health Sciences, Oncology

Abstract

This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4–6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.